Christopher Boyer

Christopher Boyer is Managing Director of Drake Partners, LLC, a Boston-based medical-device investment and management firm structured as a startup private-equity and management-consulting shop. In that role he led the commercial activities of the firm's portfolio companies, drawing on relationships across the medical-device industry and Drake Partners' network of legal, accounting, tax, and regulatory professionals. The firm's model combines direct equity participation and working-capital support with hands-on operating help spanning market analysis, fund-raising, regulatory approval, rapid prototyping, product development/manufacturing, and commercial launch.

Boyer's career is rooted in medical-device sales and marketing leadership. Before and around his Drake Partners tenure (which public records place in the mid-2010s), he was Vice President at NeuroTherm, Inc., where he transformed the sales and marketing organizations to accelerate revenue growth — work that contributed to NeuroTherm's acquisition by St. Jude Medical (now part of Abbott). He then served as a Vice President at St. Jude Medical, managing the commercial integration of NeuroTherm. Earlier, he held marketing roles of increasing responsibility at Smith & Nephew and Stryker, two of the largest publicly held device companies.

In May 2020, Boyer was appointed Vice President of Global Marketing at BrainsWay Ltd., the neurostimulation company known for its Deep Transcranial Magnetic Stimulation (dTMS) platform and its FDA-cleared indications for depression, OCD, and smoking addiction. At BrainsWay he was responsible for worldwide marketing and corporate go-to-market strategy. He is described as bringing more than 15 years of medical-device marketing and business-development expertise across both venture-backed startups and large public device companies.

Boyer is a U.S. Military Academy (West Point) graduate with a B.S. in Mathematical Sciences and a former U.S. Army field-artillery captain who was awarded the Bronze Star Medal. That combination — operational military leadership plus device commercialization — is the through-line of both his operating and investing work.

• Invests through Drake Partners at the seed stage in early-stage medical-device and healthcare-technology companies, pairing capital with operating help.
• Positions the firm as more than a check-writer: Drake Partners provides "direct equity participation and working capital" alongside management consulting on regulatory approval, product development, manufacturing, launch, and commercial distribution — a fit for founders who need commercialization muscle, not just money.
• Emphasis on business development through M&A, deal structuring, and execution of successful exit strategies — signaling a bias toward companies with a credible path to acquisition (mirroring his NeuroTherm→St. Jude experience).
• Typical seed check appears modest (~$250K), consistent with an angel/early-stage profile and syndicated fund vehicles (e.g., the Drake Partners Beta Fund).